, Volume 14, Issue 3, pp 741–749 | Cite as

Why Psychiatry Needs 3,4-Methylenedioxymethamphetamine: A Child Psychiatrist’s Perspective

  • Ben Sessa
Open Access


Since the late 1980s the psychoactive drug 3,4-methylenedioxymethamphetamine (MDMA) has had a well-known history as the recreationally used drug ecstasy. What is less well known by the public is that MDMA started its life as a therapeutic agent and that in recent years an increasing amount of clinical research has been undertaken to revisit the drug’s medical potential. MDMA has unique pharmacological properties that translate well to its proposed agent to assist trauma-focused psychotherapy. Psychological trauma—especially that which arises early in life from child abuse—underpins many chronic adult mental disorders, including addictions. Several studies of recent years have investigated the potential role of MDMA-assisted psychotherapy as a treatment for post-traumatic stress disorder, with ongoing plans to see MDMA therapy licensed and approved within the next 5 years. Issues of safety and controversy frequently surround this research, owing to MDMA’s often negative media-driven bias. However, accurate examination of the relative risks and benefits of clinical MDMA—in contrast to the recreational use of ecstasy—must be considered when assessing its potential benefits and the merits of future research. In this review, the author describes these potential benefits and explores the relatives risks of MDMA-assisted psychotherapy in the context of his experience as a child and adolescent psychiatrist, having seen the relative limitations of current pharmacotherapies and psychotherapies for treating complex post-traumatic stress disorder arising from child abuse.

Key Words

MDMA PTSD Psychotherapy Trauma Psychedelics addictions 

Introduction: From Child Abuse and Mental Disorder to Addictions and 3,4-Methylenedioxymethamphetamine

I am a child and adolescent psychiatrist, who also works with adults with addictions. My adult patients in their 20s, 30s, and beyond with unremitting depression, anxiety, post-traumatic stress disorder (PTSD), and substance abuse are sadly the same type of patients that I also care for as abused children. I believe it is a travesty that after 100 years of modern psychiatry we are not better at managing the roots of lifelong trauma-based disorders. There is a pervasive sense of learned helplessness within psychiatry. We dare not use the word “cure” when it comes to trauma, but rather have become expert at seeing our patients as palliative cases who present in their adolescence and keep coming back to psychiatry for the rest of their lives. We paper over the cracks of their pain with the prescribing of lifelong maintenance drugs; medicines that, if we are lucky, keep symptoms at bay but never get to the root cause of their pain: that early childhood experience of trauma. The lack of efficacy of traditional treatments—both pharmacological and psychotherapeutic—and the recognition that something must be done for these patients, has brought me to the door of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy. As a pharmacological agent MDMA has multiple complex and idiosyncratic modes of action. And in combination with psychotherapy the medicine provides the capacity to hold the traumatized patient in a state of emotional security, providing a state of empathic self-reflection in which, for the first time in their lives, they can be with their traumatic memories without being overwhelmed by the powerful negative affect that usually accompanies recall of their most frightening thoughts.

The Effect of Trauma on the Developing Child’s Brain

During those early years, the quality of a child’s attachment relationship with their primary caregiver becomes a blueprint of emotional containment that is carried into adulthood; forming the basis of intimate relationships. It is not only the ‘social services radar’ forms of abuse—physical and sexual abuse—that can disrupt this development. Emotional abuse and neglect, perhaps seen as less damaging by many, also inflicts considerable psychological damage; leaving a survivor feeling unwanted and worthless. Disruption to the early attachment relationship leaves a person vulnerable to PTSD and the other anxiety-based disorders, reducing their capacity to make and form relationships and causing lasting feelings of low self-esteem [1].

Being raised in a home environment of chaos and fear causes the sustained release of stress hormones, including cortisol, which results in the development of an exaggerated sense of fear, driven by the amygdala, and an attenuated ability to exercise a prefrontal cortex (PFC)-mediated fear extinction response [2]. PTSD is characterized by this imbalance in the PFC–amygdala dynamic [3], and seeing no way out of this cycle of fear many patients turn to substance misuse to blunt their feelings [4], and, similarly, rates of self-harm and completed suicide are high [5].

Treating Trauma-Related Disorders, Including Addictions

As medical doctors, with traditional education and methodical approaches, we are generally trained to recognize, categorize, and adjust the pathology before us. But there is no established single drug or psychotherapy treatment that gets to the root cause of trauma. Rather, we manage the individual symptoms as they emerge. If the patient presents with low mood, give an antidepressant; if they complain of poor sleep, give a hypnotic; if their moods fluctuate wildly, prescribe a mood stabilizer; and if their hypervigilance—one of the core features of PTSD—progresses into frank psychosis then prescribe an antipsychotic [6]. These drug therapies, whilst undoubtedly beneficial at relieving symptoms in many cases of PTSD, are only partially effective. There remains a staggering 50% treatment resistance for half of PTSD sufferers [7]. Similarly, the wide range of psychotherapies available to treat trauma, from cognitive behavioral therapy, to dialectical behavioral therapy to eye-movement and desensitization reprocessing, are only partially effective in some of the cases. For many, the chronicity of the disorder and the intense cluster of avoidance behaviors makes accessing those crucial traumatic memories a significant barrier to progress. By the time patients come to the attention of services, often already in the throes of addiction, they are so well-defended that thought of “being with those memories” to address and resolve them, simply triggers the knee-jerk response to fall into a dissociative state of self-preservation.

How MDMA Psychotherapy Works for Treating Trauma

MDMA is a ring-substituted phenethylamine, whose pharmacokinetics and pharmacodynamics have been well studied in humans. It exerts is effects primarily through promoting raised levels of monoamine neurotransmitters in the brain, especially serotonin, but other mechanisms are also involved. Table 1 describes the receptor profile of the drug and relates the effects to its efficacy as a psychotherapeutic agent. Increased activity at 5-hydroxytryptamine (HT)1A and 5-HT1B receptors reduces feelings of depression and anxiety, reduces the amygdala fear response, and increases levels of self-confidence [9]. Furthermore, the effect of raised serotonin at 5-HT2A receptors provides alterations in the perceptions of meanings and facilitates new ways of thinking about old experiences [10]. The effect of increased dopamine and noradrenaline is to raise levels of arousal and awareness, which increases sense of readiness and improves recall of state-dependent memories of stressful events [11]. Alongside this increase in arousal, which can motivate a user to engage in therapy, there is also a paradoxical increase in relaxation, which counters hypervigilance effects, mediated by MDMA’s action at alpha-2 receptors [12]. MDMA has also been shown to facilitate the release of oxytocin—the hormone associated with early infantile bonding and increased levels of empathy and closeness [13]. These well-documented effects of MDMA used clinically give rise to its description as an “empathogen” or “entactogen” [14].
Table 1

Relating 3,4-methylenedioxymethamphetamine’s (MDMA) psychotherapeutic effects to its unique receptor profile [8]

Receptors or brain region involved

MDMA effects

How effects relate to treatment of PTSD

Neurobiological correlates


Reduces depression and anxiety

Provides patient with an experience of positive mood and reduced anxiety in increased engagement

Release of presynaptic 5-hydroxytryptamine (5-HT) at 5-HT1A and 5-HT1B receptors

Stimulates alterations in the perceptions of meaning

Opportunity to see old problems in a new light

Optimum level of arousal

Increased activity at the 5-HT2A receptors

Dopamine and norepinephrine

Raises levels of arousal

Stimulating effect increases motivation to engage in therapy


Release of dopamine and noradrenaline

Alpha-2 adrenoreceptors

Increases relaxation

Reduces hypervigilance associated with PTSD


Increased alpha 2-adrenoceptor activity

Hormonal effects

Improves fear extinction learning

Allows reflection on traumatic memories during psychotherapy without being overwhelmed

Release of noradrenaline and cortisol


Increases emotional attachment and feelings of trust and empathy

Improved relationship between patient and therapist. Capacity to reflect on traumatic memories

Multiple factors, including release of oxytocin

More likely to use words relating to friendship, and intimacy

Generate discussion about wider aspects of the patient’s social and emotional relationships


Reduced social exclusion phenomena

Opportunity to reflect upon patients’ wider social functioning


Regional brain changes

Improved detection of happy faces and reduced detection of negative faces

Enhances levels of shared empathy and prosocial functioning

Increased PFC activation and decreased amygdala fear response

Reduced subjective fear response on recall of negative memories

Opportunity to reflect upon painful memories of trauma during psychotherapy

Decreased cerebral blood flow in the right amygdala and hippocampus

PTSD = post-traumatic stress disorder; PFC = prefrontal cortex

As a psychotropic drug, MDMA provides a remarkably consistent, subjectively positive, experience. However, when employed as a tool to treat trauma, the experience is nevertheless challenging, as, despite experiencing the positive effects of MDMA, recall of traumatic memories is often difficult. It is shorter acting than most classical psychedelic drugs [2–5 h duration compared with 4–8 h for psilocybin and 8–12 h for lysergic acid diethylamide (LSD)], it produces fewer perceptual alterations and is therefore well tolerated. MDMA produces elevated mood, increased sociability and feelings of closeness to others, greater compassion, feelings of sociability, closeness, and increased empathy for others and themselves [15, 16]. MDMA’s effect at reducing activity in the amygdala results in users experiencing a reduced fear response and greater activity in the reward pathways, suggesting less reactivity to anger and improved prosocial behavior [17, 18]. Because of the totality of MDMA’s receptor actions and associated psychological effects, providing the optimum level of arousal [19] MDMA has been dubbed “the perfect drug for psychotherapy” [20]. In combination, these effects allow the MDMA user, when the drug is taken within the security of a facilitating psychotherapeutic relationship, to be with their memories of trauma without being overwhelmed by negative affect. Within this psychotherapeutic environment the traumatized patient can begin the process of addressing their painful memories.

Is MDMA Safe or Dangerous?

Despite the popular media’s tendency to polarize and simplify MDMA’s safety profile based on recreational ecstasy use, in clinical medicine we have a more sophisticated way of looking at clinical possibility than simply asking if an intervention is safe or dangerous. After all, are knives safe? Are cars dangerous? The answer is always “It depends”. Rather, we ask the question: What are the relative risks versus the relative benefits of using this intervention at this time in this patient? All medical interventions from sticking plasters to cancer chemotherapy are both invasive and beneficial at the same time. So, rather than making inferences about the usefulness of MDMA therapy based on erroneous preconceptions about recreational ecstasy use, we must dispassionately apply the principles of evidence-based clinical governance.

When I first started writing and presenting on MDMA I would spend a significant part of my time addressing and defending MDMA therapy in response to audiences’ questions about recreational ecstasy use. But I recognize now that was folly. Clinical MDMA and recreational ecstasy use share few comparable features; whether in terms of the purity of the drug, the way it is administered, or the safety measures associated with the screening and monitoring of selected participants. After > 1600 doses of the drug being administered in a clinical setting there has been only one report of a brief, self-limiting serious adverse event [21]. Clinical MDMA is not recreational ecstasy.

However, even when we do look at recreational ecstasy we see very low rates of morbidity and mortality. In the UK, an estimated 750,000 doses of ecstasy have been consumed every weekend for the last 25 years. Yet rates of harm remain very low indeed. A study in 2003 looked at UK coroners’ reports of deaths attributed, in part, to ecstasy between 1997 and 2000 and found 81 such deaths [22]. However, only 7% of those 81 deaths involved MDMA alone. That is 6 deaths in 3 years, after some 120 million ecstasy tablets were consumed by over 1 million people.

MDMA may be acutely toxic through hyperthermia [23] or through hyponatremia [24]. The former may occur through prolonged physical exertion in a hot environment, combined with dehydration due to not consuming enough water. High temperature has also been demonstrated to further exacerbate the risk of longer-term neurotoxicity [25]. The second cause of acute toxicity is ecstasy-induced hyponatremia, in which vulnerable individuals with a genetic predisposition experience an impairment of the kidney’s normal water homeostasis mechanism. This can be further exacerbated by excessive water consumption, which can occur, ironically, because users may be overvigilant about the risk of dehydration. These harms, when observed through recreational use, highlight the recognized phenomenon that it is the prohibition of MDMA, as with other illicit drugs, that has an important bearing on the riskiness of its use. Indeed, it is arguable that the risk-averse approach of governments, driven by the scare-mongering popular media and vice versa, contributes significantly to the harms associated with recreational ecstasy use, and, as is well documented, making researching the compound unnecessarily expensive and time-consuming [26].

Postecstasy Come Down: Is it Due to MDMA?

When presenting on MDMA science, people often ask about the “mid-week blues” phenomenon. There is a well-documented narrative amongst recreational ecstasy/MDMA users community about the infamous “blue Monday” and “black Tuesday”. User forums (such as Bluelight, frequently discuss the phenomenon, describing low mood, irritability, and fatigue for several days after using the drug recreationally. But when ecstasy is taken recreationally users frequently take the drug at night, thereby missing a night’s sleep; they dance; often use other drugs, including alcohol; and often go without food. Studies prospectively assessing recreational ecstasy users have demonstrated such effects but concluded that sleep disturbance and concomitant drug use, including alcohol, explain the findings [27, 28, 29, 30]. An interesting study on a unique group of recreational MDMA users, Mormons in the USA, who use no other drugs, including alcohol, demonstrated no significant neurocognitive or mood deficits after taking the drug recreationally (T. Passie, personal communication, 2017) [31].

Many users anecdotally cite the “serotonin depletion” argument for their symptoms, which hypothetically sounds like a reasonable theory to explain post-MDMA low affect. But there is little data for this hypothesis. There have not been any studies looking at serotonin in humans in the days after MDMA. Franz Vollenweider, MDMA researcher for the Heffter Institute in Switzerland, has done the only clinical study of MDMA and the serotonin transporter, SERT, in humans and found no change in SERT binding after 1 month [32].

This issue of “mid-week blues” highlights, again, the folly of making inferences about the relative effects and risks of MDMA based on the anecdotal reports of recreational ecstasy users. When pure clinical MDMA is delivered during the day, with no missed sleep and a good evening meal afterwards, as is the pattern of dosing when it is used clinically, do significant numbers of people complain of postsession low affect? Or are most cases of Monday blues simply an artifact of recreational use?

We turn to clinical studies with MDMA to explore this question. George Greer conducted open-label studies with subjects receiving group and individual therapies with MDMA in the early 1980s before the drug was banned. Participants took pure MDMA, did not miss out on sleep, and did not dance. Most people reported low energy for a day or so after their daytime sessions, but there was no significant mood disturbance (G. Greer, personal communication, 2017) [33].

In more recent double-blind controlled studies exploring MDMA-assisted psychotherapy for treatment-resistant PTSD, both the MDMA and placebo groups described fatigue, anxiety, low mood, headache, and nausea in the week after experimental sessions, with low mood being slightly more frequent in the placebo group [34]. These data do not support a clear postsession syndrome attributable only to the pharmacological effects of MDMA. Furthermore, Mithoefer (personal communication, 2017) reflects whether recreational ecstasy-induced mid-week blues may highlight the presence of unprocessed psychological process that is left stirred-up, but unresolved, without a therapeutic set and setting. However, looking more closely at the pooled outcome data of all the recent Multidisciplinary Association for Psychedelic Studies (MAPS)-sponsored MDMA/PTSD studies in which mood was assessed using the self-report Beck Depression Inventory measure, > 30% of people reported mood changes in the days after taking clinical MDMA [21]. However, it is not clear whether the reported “depressed mood” is confounded by fatigue, a commonly reported effect often experienced as low mood (I. Jerome, personal communication, 2017).

In our 2 UK-based forthcoming MDMA studies we will be examining mood and affect for 7 days after MDMA and placebo sessions, which will add further data to this interesting aspect of the effects of MDMA. At this stage, given the large numbers of ecstasy users that report mid-week blues, despite the presence of confounding factors when the drug is used recreationally, there likely is a mild effect on mood post-MDMA in a certain minority of users. This may be due to serotonin depletion, but much more robust, controlled research needs to be done on the phenomenon. A particularly interesting study would be to test affect post-MDMA in the following prospective manner, where groups A/B represent clinical MDMA and groups C/D represent recreational use of ecstasy: 1) group A: Take MDMA at 10 a.m., no exercise, sleep normally that night; 2) group B: take placebo at 10 a.m., no exercise, sleep normally that night; 3) group C: take MDMA at 10 p.m., exercise, stay up all night, missing out on sleep; 4) group D: take placebo at 10 p.m., exercise, stay up all night, missing out on sleep.

Further variations of such a study could also test the effects of missing out on food and taking concomitant drugs including alcohol. And finally, on this issue, such a study could also include groups to test the much-reported phenomenon of 5-hydroxytryptophan supplements. Anecdotally many recreational ecstasy users take 5-hydroxytryptophan as a reliever of post-MDMA low affect but the effect remains entirely untested in controlled experimental conditions with pure MDMA.

Contemporary Clinical Studies with MDMA-Assisted Psychotherapy

Before MDMA was banned in the mid-1980s psychiatrist George Greer, together with his wife and psychiatric nurse co-therapist, Requa Tolbert, carried out a series of uncontrolled case studies describing the use of MDMA with couples or in groups. They describe the drug as a tool to enhance communication and closeness [33], outlined recommended conditions for its use as therapeutic agent [35], and they described some of the subjective effects associated with its use [36].

Since the drug was banned, becoming a Schedule One substance, in 1986, research has been slow and challenging. Between 1988 and 1993 the Swiss Medical Society for Psycholytic Therapy conducted individual and group psychotherapy with MDMA. Over 100 patients with a wide range of psychiatric problems (personality, adjustment, affective and eating disorders and addiction, psychosis, and sexual deviation problems) each received an average of 8 drug-assisted sessions with MDMA or LSD. Doses of MDMA averaged 125 mg. After treatment and 19 months of follow-up > 90% of patients had experienced good or slight improvement [37]. However, in the wake of growing recreational use of ecstasy the Swiss authorities shut the project down in 1993—despite calls from the Swiss therapists to plan a more methodologically robust study. In 2009, German psychiatrist, Friederike Meckel, who had trained with the Swiss Medical Society for Psycholytic Therapy, was briefly imprisoned after being caught continuing to practice underground therapy with MDMA, LSD, and 2C-B. Although the outcomes of Dr. Meckel’s therapy were not quantitatively measured, the qualitative reports of success with her patients were strongly in favor of the benefits of psychedelic drug-assisted psychotherapy. This incident shed some light on the previously unknown scale of underground psychedelic therapy occurring in Europe [38].

In recent decades, MAPS has lead the way in global MDMA/PTSD studies and has amassed a pool of data from phase II studies in USA, Switzerland, Israel, and Canada. In their first pilot study, published by Michael Mithoefer in 2011, 20 patients with chronic PTSD, refractory to both psychotherapy and psychopharmacology, received either 2 or 3 sessions of placebo-controlled MDMA-assisted psychotherapy alongside a course of preparatory and follow-up nondrug psychotherapy. Using the Clinician-Administered PTSD Scale (CAPS) as a primary outcome measure, Mithoefer showed that at the 2 and 12-month follow-up 83% of the experimental group no longer met the criteria for PTSD compared with just 25% of the patients in the placebo group. There were no drug-related serious adverse events, adverse neurocognitive effects, or clinically significant physiological events [34]. The cohort was subsequently followed-up for an average of 42 months after the initial single course of MDMA-assisted psychotherapy. And in 2013 results of that long-term follow-up study showed that rates of remission were largely maintained, without having any further doses of MDMA since the original study. The long-term follow-up showed that 17 of the 19 subjects had sustained remission by self-report; however, by the long-term follow-up CAPS scores were obtained for only 16 of the 19, so the actual percentage of sustained remission on CAPS is not certain [39]. Also in 2013, psychiatrist Peter Oehen published the results of his MAPS-sponsored MDMA psychotherapy study for treatment-resistant PTSD. Together with co-therapist, Verena Widmer, Oehen’s was a smaller study than Mithoefer’s and although there was a definite trend in the direction of MDMA therapy being superior to placebo, at first sight the statistics failed to demonstrate a significant reduction in CAPS for the experimental subjects [40]. However, Henri Chabrol of Toulouse University looked at the data again using effect size as a measure and concluded that results were indicative of MDMA psychotherapy providing substantial improvements for treatment-resistant PTSD [41].

There have been several other clinical MDMA studies in recent years that have failed to progress in the context of the multiple complexities associated with carrying out MDMA research in today’s political climate. These include the Spanish MDMA for PTSD study, run by José Carlos Bouso in Madrid, which started in 1999 but was shut down in 2002 as a result of political pressure. Another MDMA study run by John Halpern at Harvard University planned to explore the role for MDMA to treat Anxiety Secondary to Advanced Stage Cancer. It began recruiting in 2004 but was subsequently closed owing to enrolment challenges. Another MAPS-sponsored MDMA study, in Jordan, lead by Nasser Shuriquie, has been delayed awaiting Jordanian approval to begin the project. Similarly, in Australia a team lead by Stuart Saker and Fiona MacKenzie from Sydney has since met with authoritarian resistance and failed to progress. It is also worthy of note that Dr. Charles Grob’s study of psilocybin therapy for end-stage cancer patients [42] was originally planning to use MDMA. However, Grob had concerns surrounding the potential cardiovascular risks of MDMA in a medically frail group of patients. He was also concerned that in the context of increasing negative publicity regarding growing recreational ecstasy use, there was emerging a perceived over-sensationalizing of so-called "MDMA neurotoxicity”, which might preclude clinical MDMA protocols getting a fair hearing. Grob subsequently switched to psilocybin for this study.

The Future for MDMA Clinical Research: Training MDMA Therapists

In November 2016 MAPS received approval from the Food and Drug Administration to go ahead with phase III studies, and now plan multicenter, multinational studies, including plans for several sites in the UK and Europe. Pending the starting, and eventual outcome, of these studies, MAPS states 2021 as a potential date when MDMA could be licensed for prescribed practice. In which case the field will need many new MDMA therapists in the next few years. MAPS has subsequently begun a program of therapist training, with teams based in Boulder, Colorado, and Charleston, South Carolina. Training entails various stages, which include reading the MAPS manual on how to deliver MDMA therapy for PTSD, completing the MAPS online training modules, undertaking a week-long video training watching many hours of video footage of patients undergoing MDMA therapy, taking part in role play, discussion and nondrug experiential breath-work sessions, and, finally, undergoing an MDMA and a placebo therapy session with trained guides. While it is relatively easy to organize large-scale video training and discussion groups, is a bottle-neck when it comes to getting the experiential training with MDMA. To date, only a small handful of people around the world have completed the full training.

The Cardiff Functional Magnetic Resonance Imaging MDMA Study

pt?>Whilst the forthcoming MAPS phase III studies are set to develop a firm basis for using MDMA therapy for PTSD, it is noted that the acute effects of MDMA in subjects with PTSD have never been investigated using neuroimaging techniques. In view of this, I am planning a study at Cardiff University, sponsored partially by MAPS and the Beckley Foundation, to start later in 2017. The aims are to define and explore the neural correlates of MDMA in subjects with PTSD. This will involve imaging cerebral blood flow and brain activity under task-free resting conditions and measuring brain activations in response to 2 experimental paradigms and 1 postscan measure of cognitive and emotional empathy using a randomized, double-blind, placebo-controlled, crossover method. Subjects with treatment-resistant PTSD will take MDMA (125 mg) and placebo in 2 experimental conditions separated by 2 weeks. This is an exploratory study and no additional psychotherapy will be offered. However, owing to the novel nature of the MDMA experience, the study psychiatrist and a female co-sitter, both trained in MDMA therapy, will sit with the participants in a supportive, facilitative environment until the acute effects have dissipated. We hypothesize that in the MDMA session there will be reduced amygdala and increased PFC activity that will positively correlate with subjective ratings of the intensity of the MDMA experience.

Is There a Role for MDMA Therapy for Addictions?

Despite the rich history of classical psychedelics to treat addictions, MDMA has never been studied for this proposed use. There have been scant animal studies on the subject, with just 1 study showing an attenuation of alcohol use in rats after administration with MDMA [43]. In our proposed UK-based study, we postulate that MDMA-assisted psychotherapy could be useful in treating alcohol use disorder through its capacity to enhance the psychotherapeutic process or indirectly through augmenting the treatment of comorbid psychological conditions commonly associated with alcohol dependence [44]. In Greers’ report in the mid-1980s MDMA users, who were not specifically from a substance misuse population, reported reduced substance use after at least 1 session of MDMA-assisted psychotherapy, with 14 of 29 patients reporting a decreased desire for substances such as alcohol, cannabis, and caffeine [33]. A recent study in a naturalistic setting with recreational MDMA users has shown enhanced prosocial attitudes towards the self, especially for patients with pre-existing histories of trauma [45]. This capacity for MDMA to increase feelings of empathy and compassion for the self and others may also contribute to improved self-awareness and subsequently reduce the denial of alcohol abuse. Similarly, Mithoefer (personal communication, 2017) described MDMA’s capacity to “make yourself present in the moment”, which is a core concept of mindfulness. And in recent years mindfulness techniques, which encourage awareness and acceptance of thoughts, promote nonjudgmental acceptance of moment-to-moment thoughts can therefore help the alcohol addict to interrupt the tendency to react to cravings with alcohol use [46, 47, 48].

But will MDMA for addictions work? Drug-assisted psychotherapies with the “classical” psychedelic compounds, such as LSD and psilocybin, have found that the subjective mystical/spiritual effects of the psychedelic experience are strongly associated with maintained abstinence from substance use [49, 50, 51]. However, there is a subjective spiritual/mystical experience associated with MDMA use, albeit generally less so than with “classicals” [52, 53]. Furthermore, not all patients are able to tolerate the perceptually disturbing effects of the classical psychedelic experience, or even the idea of a treatment involving ‘classicals’, and compliance is a critical part of addiction therapy. Therefore, MDMA offers an alternative opportunity for enhanced psychotherapy.

This year in Bristol, UK, we will use an open-label design and aim to recruit 20 patients with alcohol use disorder who have completed a successful community detoxification to a 10-week program consisting of 2 sessions of MDMA-assisted therapy and 8 sessions of non-MDMA-assisted therapy. The study will test if MDMA-assisted psychotherapy is feasible in this patient group, if it is tolerated and if it can be delivered safely in a clinical setting, offering patients a potential new approach to this devastating, chronic, and relapsing condition.

The Importance of Tackling Misinformation and Stigma

Whenever a young person dies from a drug-related event involving ecstasy it tends to make the front page, which exaggerates the relative risks of ecstasy—and bears little resemblance to clinical MDMA. Annually in the UK there are around 9000 alcohol-related [54] and 80,000 tobacco-related deaths [55]. Nevertheless, the tremendous public relations “success” of the sustained War on Drugs continues to contribute to many negatively biased attitudes towards MDMA and other psychedelic substances, whilst disregarding the great harms done by legal drugs.

By way of an illustration of the fears surrounding psychedelic medicine, when I was presenting at a conference in 2015 to the Royal College of Psychiatrists about the benefits of psychedelics, a concerned emergency room doctor in the audience stuck up his hand and expressed his displeasure at hearing me suggest that LSD was relatively safe. He described what he considered a dangerous incident, in which a young person came into the emergency room having taken 17 tabs of acid. The young person had removed his clothes and was performing somersaults in the hospital corridors. I asked the doctor whether the young person required admission to hospital or subsequent referral to psychiatric services. “No”, he said, “After several hours of monitoring he was allowed home under the supervision of his friends and he required no further follow-up”. I put it to the challenging doctor what might have been the scenario had someone attended his department having overdosed on 17 g of cocaine, 17 g of heroin, or, for that matter, 17 bottles of wine? The doctor acknowledged that under those scenarios such a person would have ended up in intensive care or could have easily died. “So,” I said to the audience member, “here is a young person who took 17 times the recommended dose of a substance and the only pathology was that he was performing naked somersaults?”

There exist many erroneous fears about the toxicity of psychedelics. Whilst no drug is 100% safe, it is inexcusable when one comes across fellow medical colleagues whose knowledge and assumed fears of psychedelics are based wholly on media-driven preconceptions rather than evidence-based facts.

Conclusion: A Return to Those Abused Children

We are today at a place in psychiatry where general medicine was 100 years ago. In the late nineteenth century patients were dying from infectious diseases, but the medical profession was yet to discover the miracle cure of antibiotics. We knew all about the epidemiology of smallpox, tuberculosis, and postoperative infections, but Victorian physicians were powerless to stop them. Then in the twentieth century antibiotics were discovered and this transformed the face of general medicine. Today in modern psychiatry we are similarly expert at the diagnosis, classification, and categorization of our common mental diseases. As psychiatrists, we write detailed manuals for the diagnosis and categorization of our common disorders: depression, anxiety and addictions. And we well-understand the common etiological roots of these disorders: childhood trauma. But our current best treatments are unsuccessful at effecting a lasting cure for trauma. Instead we provide a wide pharmacopeia of medications, from antidepressants to mood stabilizers to antipsychotics and hypnotics, which do little more than mask the symptoms of the underlying psychological problems.

Psychedelic therapies—and particularly MDMA-assisted psychotherapy for tackling underlying trauma—that aim not simply to paper symptomatically over the cracks of trauma, but rather provide an opportunity for patients for the first time in their lives to address and resolve those traumatic childhood memories, could be as transformative for twenty-first-century psychiatry as antibiotics were 100 years ago. We owe it to that population of patients—my patients suffering since childhood—to carry out this research.



Teri Krebs, Michael Mithoefer, George Greer, Thomas Roberts, Alicia Danforth, and Tortsen Passie.

Supplementary material

13311_2017_531_MOESM1_ESM.pdf (510 kb)
ESM 1 Required Author Forms Disclosure forms provided by the authors are available with the online version of this article. (PDF 510 kb)


  1. 1.
    Lee, A., Hankin, B. L. (2009). Insecure attachment, dysfunctional attitudes, and low self-esteem predicting prospective symptoms of depression and anxiety during adolescence. J Clin Child Adolesc Psychol 38(2), 219–231.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Streeck-Fischer A, van der Kolk B. (2000) Down will come baby, cradle and all: diagnostic and therapeutic implications of chronic trauma on child development. Aust N Z J Psychiatry 2000; 34(6):903-918CrossRefGoogle Scholar
  3. 3.
    Rauch SL, Whalen PJ, Shin LM, (2000) Exaggerated amygdala response to masked facial stimuli in posttraumatic stress disorder: a functional MRI study. Biol Psychiatry 47(9):769–776CrossRefPubMedGoogle Scholar
  4. 4.
    Brady, KT, Back SE, Coffey SF. (2004). Substance abuse and posttraumatic stress disorder. Curr Dir Psychol Sci13, 206-209.CrossRefGoogle Scholar
  5. 5.
    Ferry F, Bolton D, Bunting B, Devine B, McCann S, Murphy S. (2008) Trauma, health and conflict in Northern Ireland: a study of the epidemiology of trauma related disorder and qualitative investigation of the impact of trauma on the individual. The Northern Ireland Centre for Trauma and Transformation and the Psychology Research Institute, University of Ulster. Available at: Accessed 13 April 2017.
  6. 6.
    NCCMH (2005). Post-traumatic stress disorder: the management of PTSD in adults and children in primary and secondary care. Vol. 26, London: Gaskell and the British Psychological Society. Clinical guidelines, CG26 - Issued: March 2005Google Scholar
  7. 7.
    Hoskins MD, Pearce J, Bethell A, et al. (2014) Pharmacotherapy for post-traumatic stress disorder: a systematic review and meta-analysis. Br J Psychiatry 2015, 206 (2) 93-100Google Scholar
  8. 8.
    Sessa, B. (2016) MDMA and PTSD treatment: PTSD: From novel pathophysiology to innovative therapeutics. Neurosci Lett 2016 Jul 6. pii: S0304-3940(16)30490-6.Google Scholar
  9. 9.
    Brunner D, Hen R. (1997) Insights into the neuro-biology of impulsive behavior from serotonin receptor knockout mice. Ann NY Acad Sci 1997;836:81-105CrossRefGoogle Scholar
  10. 10.
    Nash JF, Roth BL, Brodkin JD, et al. (1994) Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors. Neurosci Lett 1994;177:111-115CrossRefGoogle Scholar
  11. 11.
    Cozzi NV, Sievert MK, Shulgin AT, et al. (1999) Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. Eur J Pharmacol 1999;381:63-69.Google Scholar
  12. 12.
    Lavelle A, Honner V, Docherty JR. (1999) Investigation of the prejunctional alpha2-adrenoceptor mediated actions of MDMA in rat atrium and vas deferens. Br J Pharmacol 1999;128:975-980Google Scholar
  13. 13.
    Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS. (2007) A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy"). Neuroscience; 146(2): 509-514.CrossRefPubMedGoogle Scholar
  14. 14.
    Nichols DE. (1986). Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. identification of a new therapeutic class: entactogens. J Psychoactive Drugs 18(4): 305–313.CrossRefPubMedGoogle Scholar
  15. 15.
    Harris DS, Baggott M, Mendelson JH, Mendelson JE, Jones RT. Subjective and hormonal effects of 3,4- methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 2002; 162(4): 396-405.CrossRefGoogle Scholar
  16. 16.
    Hysek CM, Schmid Y, Simmler LD, et al. (2013) MDMA enhances emotional empathy and prosocial behavior. Soc Cogn Affect Neurosci ;9(11):1645-1652CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Gamma A, Buck A, Berthold T, Liechti ME, Vollenweider FX. (2000) 3,4- Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H(2)(15)O]-PET in healthy humans. Neuropsychopharmacology 23: 388-395.CrossRefPubMedGoogle Scholar
  18. 18.
    Hysek CM, Domes G, Liechti ME. (2012) MDMA enhances “mind reading” of positive emotions and impairs “mind reading” of negative emotions. Psychopharmacology 222: 293-302.CrossRefPubMedGoogle Scholar
  19. 19.
    Foa EB, Keane TM, Friedman MJ, Cohen JA. (2009) Effective treatments for PTSD, practice guide- lines from the International Society for Traumatic Stress Studies, 2nd edn. New York, NY: Guilford Press.Google Scholar
  20. 20.
    Sessa B. (2011) Can MDMA enhance Trauma-focused psychotherapy? Prog Neurol Psychiatry 15: 4–7.CrossRefGoogle Scholar
  21. 21.
  22. 22.
    Schifano F, Oyefeso A, Webb L, Pollard M, Corkery J, Ghodse AH. (2003) Review of deaths related to taking ecstasy, England and Wales, 1997–2000. BMJ 326: 80–81CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Nimmo SM. Kennedy BW, Tullett WM, Blyth AS, Dougall JR. (1993) Drug- induced hyperthermia. Anaesthesia 48: 892–895.CrossRefPubMedGoogle Scholar
  24. 24.
    Wolff K, Tsapakis EM, Winstock AR, et al. (2006) Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population. J Psychopharmacol 20(3): 400–410CrossRefPubMedGoogle Scholar
  25. 25.
    Malberg JE, Seiden LS (1998) Small changes in ambient temperature causes large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neuroscience 18: 5086–5094PubMedGoogle Scholar
  26. 26.
    Sessa B, Nutt DJ (2007) MDMA, politics and medical research: Have we thrown the baby out with the bathwater? J Psychopharmacol 21: 787–791.CrossRefPubMedGoogle Scholar
  27. 27.
    Curran HV, Travill RA. (1997) Mood and cognitive effects of ±3,4--methylenedioxymethamphetamine (MDMA, ‘ecstasy’): week-end ‘high’ followed by mid-week low. Addiction 1997;92(7):821–831.Google Scholar
  28. 28.
    Scott RM, Hides L, Allen JS, Lubman DI. (2013) Subacute effects of ecstasy on mood: an exploration of associated risk factors. J Psychopharmacol. 2013;27(1):53-61Google Scholar
  29. 29.
    Pirona A, Morgan MJ. (2010) An investigation of the subacute effects of ecstasy on neuropsychological performance, sleep and mood in regular ecstasy users. J Psychopharmacol 2010;24(2):175-85Google Scholar
  30. 30.
    Huxster JK, Pirona A, Morgan MJ. (2006) The sub-acute effects of recreational ecstasy (MDMA) use: a controlled study in humans. J Psychopharmacol 2006;20(2):281-90Google Scholar
  31. 31.
    Halpern JH, Pope HG, Sherwood AR, Barry S, Hudson JI, Yurgelun TD (2004) Residual neuropsychological effects of illicit 3,4- methelenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs. Drug Alcohol Dependency 75:135–147CrossRefGoogle Scholar
  32. 32.
    Vollenweider FX, Gucker P, Schönbächler R, et al. (2000). Effects of MDMA on 5-HT uptake sites using PET and [11C]-McN5652 in humans. Data presented at 2000 conference of the German Society for Psychiatry, Psychotherapy and Neuromedicine [Deutsche Gesellschaft für psychiatrie, Psychotherapie und Nervenheilkunde, 2000].Google Scholar
  33. 33.
    Greer G, Tolbert R. (1986). Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 18 (4), 319-327CrossRefPubMedGoogle Scholar
  34. 34.
    Mithoefer MC, Wagner TM, Mithoefer AT, Jerome L, Doblin R (2011) The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study 25(4): 439–452. J PsychopharmacolCrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Greer, G. (1985) Using MDMA in psychotherapy. Advances 2 (2), 57-59Google Scholar
  36. 36.
    Greer, G., Tolbert, R. (1990). The therapeutic use of MDMA. In S.J. Peroutka (Ed.), Ecstasy: The clinical, pharmacological and neurotoxicological effects of the drug MDMA (pp. 21-36). Boston: Kluver Academic Publishers.CrossRefGoogle Scholar
  37. 37.
    Gasser, P. (1995) Psycholytic Therapy with MDMA and LSD in Switzerland. Newsletter of the Multidisciplinary Association for Psychedelic Studies MAPS - Volume 5 Number 3 Winter 1994-95 - pp. 3-7Google Scholar
  38. 38.
    Sessa, B and Fischer, F. (2015) Underground LSD, MDMA and 2-CB-assisted Individual and Group Psychotherapy in Zurich: Outcomes, Implications and Commentary. J Psychopharmacol March 2015. Vol1Google Scholar
  39. 39.
    Mithoefer, MC, Wagner, MT, Mithoefer, AT, et al. (2013) Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependence after 3,4-methylenedioxymeth- amphetamine-assisted psychotherapy: a prospective long-term follow- up study. J Psychopharmacol 27(1):28-39CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Oehen P, Traber, R., Widmer, V., Schnyder, U. (2013) Pilot study of MDMA-assisted psychotherapy for treatment-resistant PTSD. J Psychopharmacol 27(1): 40-52CrossRefPubMedGoogle Scholar
  41. 41.
    Chabrol H, Oehen, P. (2013) MDMA assisted psychotherapy found to have a large effect for chronic post-traumatic stress disorder. J Psychopharmacol; s27(9):865-866CrossRefGoogle Scholar
  42. 42.
    Grob, C., Chopra, A.L. Danforth, M.C. et al. (2010) Pilot Study of Psilocybin Treatment for Anxiety in Advanced-stage Cancer Patients. Arch Gen Psychiatry, 68(1):71-78CrossRefPubMedGoogle Scholar
  43. 43.
    Rezvani, A.H., Garges, P.L., Miller, D.B., Gordon C.J. (1992) Attenuation of alcohol consumption by MDMA (Ecstasy) in two strains of alcohol-preferring rats. Pharmacol Biochem Behav Vol 43, pp. 103-110CrossRefPubMedGoogle Scholar
  44. 44.
    Jerome, L, Schuster, S, Berra Yazar-Klosinski, B. (2013) Can MDMA play a role in the treatment of substance abuse? Curr Drug Abuse Rev 2013, 6.Google Scholar
  45. 45.
    Stolaroff M. (2004) The Secret Chief Revealed: Conversations with a pioneer of the underground therapy movement. Chapter 2, pages 45-49. Multidisciplinary Association for Psychedelic Studies, Sarasota, USAGoogle Scholar
  46. 46.
    Marcus, M.T., Zgierska, A. (2009). Mindfulness-based therapies for substance use disorders: part 1 (editorial). Substance Abuse 30(4), 263CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Hsu SH, Grow J, Marlatt GA. (2008) Mindfulness and addiction. In: Galanter M, Kaskutas LA, editors. Recent Developments in Alcoholism. Vol. 18. pp. 229–250Google Scholar
  48. 48.
    Shapiro SL, Carlson LE, Astin JA, Freedman, B. Mechanisms of mindfulness. J Clin Psychol 2006;62(3):373–383CrossRefPubMedGoogle Scholar
  49. 49.
    Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. (2015) Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015;29(3):289-299.CrossRefPubMedGoogle Scholar
  50. 50.
    Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR3 (2014) Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol 28(11):983-992Google Scholar
  51. 51.
    Krupitsky EM, Grinenko AY (1997). ‘Ketamine psychedelic therapy (KPT): a review of the results of ten years of research’. J Psychoactive Drugs 29: 165–183CrossRefPubMedGoogle Scholar
  52. 52.
    Watson, L., Beck, J. (1991) New age seekers: MDMA as an adjunct to spiritual pursuit. J Psychoactive Drugs 23(3).Google Scholar
  53. 53.
    Sumnall, H. R, Cole, J., Jerome, L. (2006) The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy. J Psychopharmacol 20 (5): 670–682CrossRefPubMedGoogle Scholar
  54. 54.
    Office of National Statistics (ONS) (2014) – Alcohol Related Deaths in the United Kingdom: Registered in 2014.Google Scholar
  55. 55.
    Health and Social Care Information Centre (HSCIC) (2016) Statistics on Smoking: England, 2016 - Health and social care.Google Scholar

Copyright information

© The Author(s) 2017

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.Psychopharmacology Department, Department of MedicineImperial College London UniversityLondonUK

Personalised recommendations